A Phase 1, Randomized, Double-Blind, Placebo-Controlled, 2-Period, Cross-Over Single Day Evaluation Of The Pharmacokinetic-Pharmacodynamic Effect Of Once And Twice Daily Oral Administration Of PF-04971729 In Patients With Type 2 Diabetes Mellitus.

Trial Profile

A Phase 1, Randomized, Double-Blind, Placebo-Controlled, 2-Period, Cross-Over Single Day Evaluation Of The Pharmacokinetic-Pharmacodynamic Effect Of Once And Twice Daily Oral Administration Of PF-04971729 In Patients With Type 2 Diabetes Mellitus.

Completed
Phase of Trial: Phase I

Latest Information Update: 25 May 2016

At a glance

  • Drugs Ertugliflozin (Primary)
  • Indications Type 2 diabetes mellitus
  • Focus Adverse reactions; Pharmacodynamics; Pharmacokinetics
  • Sponsors Merck Sharp & Dohme
  • Most Recent Events

    • 07 Jun 2017 Biomarkers information updated
    • 23 Apr 2010 Actual end date (April 2010) added as reported by ClinicalTrials.gov.
    • 23 Apr 2010 Status changed from recruiting to completed as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top